Embracing LEAN strategy to deliver patient-critical expanded access
Expanded access or compassionate use of investigational drugs provides a lifeline to certain patients, improving their quality of life or extending life expectancy. Yet it can also present clinical supply chain challenges and increase pressure on manufacturing operations to deliver vital therapeutic drugs, outside of normal procedures.
This was the case for one small, clinical stage biopharmaceutical company committed to developing treatments for a group of rare and ultimately fatal diseases. During phase I of a blinded trial, a patient was identified as a compassionate use case and Almac was committed to expediting drugs that were needed to halt the progression of the patient’s disease.
Download our latest Case Study to find out how Almac Clinical Services used a LEAN approach to drastically shorten the standard timelines associated with packaging and labelling drugs for the compassionate use patient.
If you require any further information, please contact Almac Clinical Services.View Resource
Almac Clinical Services
Guided by our extensive clinical supply experience and expertise, Almac Clinical Services is recognised as an innovative, global solution provider within the specialised and complex market of clinical trial supply.
Our integrated and adaptable solutions offer the most flexible approach to support the delivery of global clinical trials from protocol right through to patient delivery.
Our core purpose is to be the partner of choice, to deliver the next generation of health care solutions effectively and to focus on winning for you and your patients.